Zobrazeno 1 - 10 of 38 pro vyhledávání: '"S D Reich"'
1
In vivo biological response to recombinant interferon-gamma during a phase I dose-response trial in patients with metastatic melanoma
Autor: J. Schindler, G. Hebert, Y. Nishida, J. Balzer, John M. Kirkwood, T. Trautman, Marc S. Ernstoff, S D Reich, C. A. Davis, S. A. Rudnick
Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 8(6)
Interferon-gamma (IFN gamma), as produced by recombinant DNA technology, has shown a wide range of immunomodulatory activity in vitro and in vivo. Clinical studies have attempted to establish a dose-response relationship to define optimal dosage rang
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba1fd66f2bed9e19ce1756f3944b852a
https://pubmed.ncbi.nlm.nih.gov/2112184
Zobrazit plný text záznamu
2
Phase I study of ATN-224 in patients (pts) with advanced solid tumours
Autor: A P Mazar, Mark R. Middleton, C Hayward, S A Lowndes, S D Reich, A Timms, A Adams, Adrian L. Harris
Publikováno v: Web of Science
2065 Background: Copper chelation reduces the secretion of many angiogenic factors and reduces tumour growth and microvascular density in animal models. ATN-224 is a second generation analogue of ammonium tetrathiomolybdate, which reportedly can stab
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5eb70540d2c9796a7c7f57592fd8bf21
https://doi.org/10.1200/jco.2006.24.18_suppl.2065
Zobrazit plný text záznamu
3
First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors
Autor: Mark R. Middleton, Chris Jones, Heidi Steinfeldt, R Kaufman, Alan Hilary Calvert, J. Evans, Ruth Plummer, L Robson, S. D. Reich, Richard K. Wilson
Publikováno v: Journal of Clinical Oncology. 23:3065-3065
3065 Background: AG-014699 inhibits poly(ADP-ribose) polymerase (PARP) is a key enzyme in DNA repair. AG-014699 sensitizes cancer cells to DNA damaging drugs such as TMZ. AG-014699 is the first PARP inhibitor to be evaluated in cancer patients. Metho
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::986dc971266c8d5fa9816e20a1606c26
https://doi.org/10.1200/jco.2005.23.16_suppl.3065
Zobrazit plný text záznamu
4
Results of 2 phase I studies of intravenous (iv) pelitrexol (AG2037), a glycinamide ribonucleotide formyltransferase (GARFT) inhibitor, in patients (pts) with solid tumors
Autor: S. D. Reich, F. Robert, M. Amantea, William R. Dinwoodie, Daniel M. Sullivan, M. Zhang, M. Bishop, Christopher R. Garrett
Publikováno v: Journal of Clinical Oncology. 22:3075-3075
3075 Background: AG2037 is a rationally designed, novel inhibitor of GARFT, which is an essential enzyme in the de novo synthesis of purines, a critical process for cell growth. Methods: The primary objectives of these studies were to determine the m
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::106399f599d06f01bda7aa3f361da633
https://doi.org/10.1200/jco.2004.22.90140.3075
Zobrazit plný text záznamu
5
Clinical and dynamic imaging results of the first phase I study of AG–013736, an oral anti-angiogenesis agent, in patients (pts) with advanced solid tumors
Autor: Merrill S. Kies, Hope S. Rugo, G. Wilding, S. D. Reich, Glenn Liu, Roy S. Herbst, John W. Park, T. M. McShane, Heidi Steinfeldt, Yazdi K. Pithavala
Publikováno v: Journal of Clinical Oncology. 22:2503-2503
2503 Background: AG-013736 is a potent and selective inhibitor of VEGF and PDGF receptor tyrosine kinases with broad preclinical activity in xenograft models of solid tumors. Methods: The primary objective was to determine maximum tolerated dose (MTD
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::106427a02a571a960e0b23fff0efe660
https://doi.org/10.1200/jco.2004.22.90140.2503
Zobrazit plný text záznamu
6
A randomized phase I/II study of continuous versus intermittent intravenous interferon gamma in patients with metastatic melanoma
Autor: C. A. Davis, John M. Kirkwood, J Balser, S D Reich, T. Trautman, P Witman, S. A. Rudnick, Marc S. Ernstoff
Publikováno v: Journal of Clinical Oncology. 5:1804-1810
Thirty patients with documented metastatic melanoma were randomly assigned to receive recombinant DNA-produced gamma-interferon (specific activity approximately, 20 MU/mg) intravenously (IV) over either two or 24 hours at dosages of 3, 30, 300, 1,000
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ff2892ed0ed3edeedebcc8659ad0a26
https://doi.org/10.1200/jco.1987.5.11.1804
Zobrazit plný text záznamu
8
Alterations in adriamycin efficacy by phenobarbital
Autor: S D, Reich, N R, Bachur
Publikováno v: Cancer research. 36(10)
Adriamycin dosage should be reduced in patients with impaired liver function, since adriamycin disposition is influenced by liver metabolism and biliary excretion. It follows that drugs that increase the metabolism or excretory capacity of the liver
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::544ef869a154010a69e1b85c8b7f27bf
https://pubmed.ncbi.nlm.nih.gov/954004
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje